Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 11/20 | 0.51 |
| ▸ | RAB9A | P51151 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25334427 | 0.96 | HCAR2 (0.70) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL22887837 | 0.94 | TSHR (0.71) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL31539683 | 0.94 | TSHR (0.71) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL1663622 | 0.82 | HCAR2 (1.00) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL21764920 | 0.81 | HCAR2 (0.70) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL22518545 | 0.80 | HCAR2 (0.64) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL30092755 | 0.80 | HCAR2 (0.46) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL30824039 | 0.80 | HCAR2 (0.49) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL5952125 | 0.78 | HCAR2 (1.00) | HCAR2KMT2ATSHRGAARXFP1 | |
| SCHEMBL14648769 | 0.77 | HCAR2 (0.70) | HCAR2KMT2ATSHRGAARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853674-A | Production method of medical intermediate 1,4,5, 6-tetrahydro-3-cyclopentapyrazole formonitrile | 浙江安贝特药业有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-114853674-B | Production method of medical intermediate 1,4,5, 6-tetrahydro-3-cyclopentapyrazole carbonitrile | 浙江安贝特药业有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-114853674-A | Production method of medical intermediate 1,4,5, 6-tetrahydro-3-cyclopentapyrazole formonitrile | 浙江安贝特药业有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-8637555-B2 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637555-B2 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637555-B2 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | ARENA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | ARENA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | ARENA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20070072924-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072924-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072924-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20060217562-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| EP-1683794-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | Arena Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1599469-B1 | TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARM INC (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006052569-A1 | COMPOSITIONS FOR TREATING FLUSHING AND LIPID-ASSOCIATED DISORDERS COMPRISING NIACIN RECEPTOR PARTIAL AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006026273-A2 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1599469-A1 | TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005044816-A1 | TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072924-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | SQLE, ACE, AGTR2 | HCAR2 223/4885KMT2A 4044/4885TSHR 1547/4885 |
| US-20060217562-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | SQLE, ACE, AGTR2 | HCAR2 223/4885KMT2A 4044/4885TSHR 1547/4885 |
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | FFAR1, FFAR2, FFAR3 | HCAR2 11/4885KMT2A 1795/4885TSHR 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.